Access
This article is part of Nature's premium content.
Published online 23 February 2009 | 457, 1064-1065 (2009) | doi:10.1038/4571064a
News
Drug patent plan gets mixed reviews
GlaxoSmithKline's bid to tackle neglected diseases receives a muted response from the rest of the industry.
Proposals to radically change the way the drug industry approaches neglected tropical diseases have prompted intense debate within the sector.
Andrew Witty, chief executive of GlaxoSmithKline (GSK), outlined the suggestions in a speech on 13 February at Harvard Medical School in Boston, Massachusetts.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
